Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Esophageal CancerGastroesophageal Cancer
Interventions
DRUG

5-Fluorouracil

"Arm A = 250 mg/m\^2 IV over 24 hours for 5 days weekly for 5 weeks.~Arm B = 2.2 mg/m\^2 IV over 48 hours on days 1 and 15."

DRUG

Oxaliplatin

"Arm A: 40 mg/m\^2 IV daily over 2 hours for 5 weeks~Arm B: 100 mg/m\^2 IV on Day 1 and 15"

RADIATION

Radiation Therapy

Radiation treatment every weekday for 5 weeks.

PROCEDURE

Surgery

Surgical removal of the primary tumor and lymph nodes following completion of disease status evaluation post chemotherapy and radiation treatments.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00525915 - Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma | Biotech Hunter | Biotech Hunter